Get the Stockscreener App
40.00
0.38%
0.15
Lenz Therapeutics Inc stock is traded at $40.00, with a volume of 663.48K.
It is up +0.38% in the last 24 hours and up +21.29% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$39.85
Open:
$40.22
24h Volume:
663.48K
Relative Volume:
1.64
Market Cap:
$1.14B
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-7.1463
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
+5.68%
1M Performance:
+21.29%
6M Performance:
+70.29%
1Y Performance:
+80.02%
1-Day Range:
$39.27
$41.26
1-Week Range:
$36.30
$41.26
52-Week Range:
$16.54
$41.70
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
40.00 | 1.11B | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
News impact scoring models applied to LENZ Therapeutics Inc.Market Sentiment Report & Real-Time Buy Signal Notifications - Newser
Real time breakdown of LENZ Therapeutics Inc. stock performanceQuarterly Market Summary & Verified Momentum Watchlists - Newser
Analyzing LENZ Therapeutics Inc. with risk reward ratio charts2025 Valuation Update & Trade Opportunity Analysis Reports - Newser
How to build a dashboard for LENZ Therapeutics Inc. stockQuarterly Market Summary & High Return Stock Watch Alerts - Newser
Relative strength of LENZ Therapeutics Inc. in sector analysis2025 Key Highlights & Detailed Earnings Play Alerts - Newser
LENZ Therapeutics Inc. stock outlook for YEARGold Moves & Weekly Chart Analysis and Guides - Newser
What MACD and RSI say about LENZ Therapeutics Inc.Market Performance Summary & Verified Chart Pattern Trade Signals - Newser
Using data tools to time your LENZ Therapeutics Inc. exitEarnings Recap Summary & Reliable Entry Point Trade Alerts - Newser
Has LENZ Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewJuly 2025 Earnings & Reliable Entry Point Alerts - Newser
Detecting support and resistance levels for LENZ Therapeutics Inc.Weekly Profit Summary & Daily Volume Surge Trade Alerts - Newser
Will LENZ Therapeutics Inc. bounce back from current supportWeekly Investment Recap & Smart Money Movement Tracker - Newser
Traders Consider Averaging Down in LENZ Therapeutics Inc.July 2025 Rallies & High Win Rate Trade Tips - 선데이타임즈
Developing predictive dashboards with LENZ Therapeutics Inc. data2025 Market Trends & Weekly Consistent Profit Watchlists - Newser
Full technical analysis of LENZ Therapeutics Inc. stock2025 Breakouts & Breakdowns & Technical Pattern Recognition Alerts - Newser
LENZ Therapeutics Inc. Rebound Backed by Sentiment ShiftQuarterly Portfolio Summary & Real-Time Market Sentiment Reports - classian.co.kr
First Week of April 2026 Options Trading For Lenz Therapeutics - Nasdaq
Trend analysis for LENZ Therapeutics Inc. this weekJuly 2025 Review & Entry Point Confirmation Alerts - Newser
Will LENZ Therapeutics Inc. benefit from macro trendsWeekly Risk Report & Stock Market Timing Techniques - Newser
How to manage a losing position in LENZ Therapeutics Inc.Earnings Growth Report & Risk Managed Investment Entry Signals - Newser
Is a relief rally coming for LENZ Therapeutics Inc. holdersRate Hike & High Yield Equity Trading Tips - Newser
What makes LENZ Therapeutics Inc. stock price move sharplyQuarterly Performance Summary & AI Driven Price Forecasts - Newser
Has LENZ Therapeutics Inc. found a price floorWeekly Trend Report & AI Powered Market Entry Strategies - Newser
What high frequency data says about LENZ Therapeutics Inc.July 2025 Update & Weekly Stock Breakout Alerts - Newser
Using R and stats models for LENZ Therapeutics Inc. forecastingQuarterly Risk Review & Free Weekly Chart Analysis and Trade Guides - Newser
What MACD signals say about LENZ Therapeutics Inc.Portfolio Growth Summary & Community Shared Stock Ideas - Newser
Why LENZ Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Spike Watch & Expert Approved Trade Ideas - 선데이타임즈
LENZ Therapeutics Inc.’s volatility index tracking explained2025 Key Lessons & Consistent Growth Equity Picks - Newser
Short interest data insights for LENZ Therapeutics Inc.2025 Market Overview & Daily Oversold Bounce Ideas - Newser
Applying big data sentiment scoring on LENZ Therapeutics Inc.July 2025 Volume & Smart Allocation Stock Reports - Newser
What earnings revisions data tells us about LENZ Therapeutics Inc.Weekly Gains Summary & High Return Trade Opportunity Guides - Newser
No Need For Reading Glasses? Vizz Eye Drop That Improves Near Vision Has FDA Nod - NDTV Profit
Will LENZ Therapeutics Inc. rebound enough to break evenJuly 2025 Snapshot & AI Forecasted Entry/Exit Points - Newser
Using data models to predict LENZ Therapeutics Inc. stock movement2025 Breakouts & Breakdowns & Reliable Volume Spike Trade Alerts - Newser
Does LENZ Therapeutics Inc. qualify in momentum factor screeningQuarterly Profit Report & Risk Controlled Swing Alerts - Newser
Is LENZ Therapeutics Inc. a cyclical or defensive stockEarnings Performance Report & Accurate Trade Setup Notifications - thegnnews.com
Lenz Therapeutics stock hits 52-week high at 40.97 USD By Investing.com - Investing.com Canada
Lenz Therapeutics stock hits 52-week high at 40.97 USD - Investing.com
FDA Approves Vizz Eye Drops for Instant Near Vision Improvement - AInvest
Lenz Therapeutics shares rise 2.15% premarket after Lotus Pharmaceuticals reported a 6% revenue increase in the U.S. and Southeast Asia. - AInvest
What the charts say about LENZ Therapeutics Inc. todayJuly 2025 Levels & Risk Managed Investment Signals - Newser
Momentum Screeners Rank LENZ Therapeutics Inc. in Top 5 TodayAI Forecast for Trending Stocks Indicates Upside - beatles.ru
Evaluating LENZ Therapeutics Inc. with trendline analysisNeural Network Based Equity Prediction System - Newser
LENZ Therapeutics Scores Relative Strength Rating Upgrade - Investor's Business Daily
LENZ Therapeutics: Evaluate Stock Surge - timothysykes.com
LENZ Therapeutics Soars 11.6% on Explosive Intraday Rally: Technical Breakout or Speculative Surge? - AInvest
LENZ Therapeutics Soars 12.48% on Intraday Frenzy: Is This a Breakout or a Bubble? - AInvest
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lenz Therapeutics Inc Stock (LENZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Aug 15 '25 |
Sale |
39.50 |
69,949 |
2,762,986 |
977,963 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 18 '25 |
Sale |
38.56 |
30,628 |
1,181,049 |
1,400,220 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 18 '25 |
Sale |
38.56 |
15,085 |
581,694 |
962,878 |
| Versant Venture Capital VI, L. | 10% Owner |
Jul 10 '25 |
Sale |
34.00 |
191,376 |
6,506,784 |
1,575,899 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 27 '25 |
Sale |
30.46 |
200,000 |
6,093,000 |
1,767,275 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.25 |
133,924 |
4,051,201 |
1,967,275 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.35 |
100,877 |
3,061,617 |
1,047,912 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 18 '25 |
Sale |
29.95 |
100,000 |
2,995,000 |
1,148,789 |
| Versant Venture Capital VI, L. | 10% Owner |
Jun 10 '25 |
Sale |
29.00 |
350,000 |
10,150,000 |
1,248,789 |
| Olsson Shawn | Chief Commercial Officer |
Apr 09 '25 |
Option Exercise |
2.08 |
1,400 |
2,912 |
4,733 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):